Pfizer targets $2.5bn more in cost savings
Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
MSD records one hit, one miss with TL1A drug tulisokibart
MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
NICE breast cancer criteria missing patients, claims study
NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
Curium strikes $8bn deal to buy radiopharma rival Lantheus
Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Oncology
Patients
R&D
Partner Content
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The industry's flagship drug-CDx forum widening global precision medicine access.